1 / 20

Nonalcoholic Fatty Liver Disease

Nonalcoholic Fatty Liver Disease. s_khalilzadeh. A Novel Cardiometabolic Risk Factor for Type 2 Diabetes. NAFLD and T2DM. NAFLD is closely associated with features of the metabolic syndrome and is regarded as the hepatic manifestation

Download Presentation

Nonalcoholic Fatty Liver Disease

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Nonalcoholic Fatty Liver Disease s_khalilzadeh

  2. A NovelCardiometabolic Risk Factor for Type 2 Diabetes

  3. NAFLD and T2DM • NAFLD is closely associated with features of the metabolic • syndrome and is regarded as the hepatic manifestation • of the syndrome .The amount of intrahepatic • fat closely correlates with serum liver enzyme levels and • the number of metabolic syndrome features Patients • with T2DM have approximately 80% more intrahepatic • fat content than age-, sex-, and body weight-matched nondiabetic Controls, and their serum liver enzymes are less • representative of the severity of intrahepatic fat accumulation

  4. NAFLD AND T2DM • patients with NAFLD and T2DM are • also more likely to develop the more advanced forms of • NAFLD, such as NASH, advanced fibrosis, cirrhosis, and • in some cases hepatocellular carcinoma

  5. Poor glycemic control • Because NAFLD is strongly associated with IR, patients • With T2DM and NAFLD often have poor glycemiccontrol • compared to their counterparts without NAFLD • The presence of NAFLD in people with T2DM often • makes it difficult to obtain good glycemic control

  6. stable glycemic controlwith in insulin treated T2DM patient it has • been demonstrated that the intrahepatic triglyceride content • was more closely correlated with the daily insulin dose • and the ability of insulin to suppress hepatic glucose production • and better explained the interindividual variation • in insulin requirements

  7. In addition, when the relationship between NAFLD • and peripheral glucose metabolism was explored in • healthy individuals, the association between the intrahepatic • triglyceride content and systemic IR was stronger • than the association with intramyocellular lipid content, • visceral fat content, or sc fat content

  8. NAFLD and risk of chronic diabetic complicationsand mortality among T2DM patients • The presence of NAFLD among patients with T2DM • appears to be an important risk factor for all-cause mortality. • A community-based study of T2DM individuals • reported that those with NAFLD had a 2.2-fold increased • risk of all-cause mortality compared with those • without NAFLD; the most common causes of death • were malignancy, CVD, and liver-related complications • Evidence is mounting that NAFLD is associated • with the presence of vascular disease, ie, the most common • cause of death in people with T2DM

  9. Evidence Linking NAFLD With Risk ofDeveloping T2DM • modestly increased serum GGT and ALT levels were independent, • long-term predictors of incident T2DM in • both sexes

  10. Treatment Options for NAFLD • Presently, there is no licensed treatment for humanNAFLD • Most interventions evaluated for the treatment • of NAFLD are those commonly used for the treatment of • T2DMand exert a rather indirect effect through improvement • in IR and glycemia

  11. Statins • statins can be used in dyslipidemic individuals with increased • baseline liver enzymes and may even produce • Some histological benefit in NASH

  12. Lifestyle modifications • gradual weight reduction, • achieved either by hypocaloric diet alone or in combination • with increased physical exercise, can be effective in • decreasing hepatic steatosis and necroinflammation (the • reduction of hepatic steatosis and necroinflammation is • proportional to the intensity of the lifestyle intervention • and generally requires a weight loss between 5 and 10%)

  13. Insulin-sensitizing agents • Metformin, the first-line choice in oral therapy for • T2DM, has beneficial effects on serum aminotransferases • and IR but has no significant effect on liver histology and • is not recommended as a specific treatment for liver disease in patients with NAFLD/NASH

  14. Insulin-sensitizing agents • Pioglitazone can • be used to treat steatohepatitis in patients with biopsyproven NASH; • there are no randomized clinical trials with • histological endpoints that investigated pioglitazone to • specifically t reat patients with NAFLD. A recent metaanalysis • reported that pioglitazone improved steatosis and • necroinflammation, but not fibrosis

  15. Omega-3 polyunsaturated fatty acid (PUFA)supplementation • supplementation • High doses of omega-3 PUFAs are effective in treating • hypertriglyceridemia that is often a feature of NAFLD and • T2DM.

  16. Glucagon-like peptide agonist (GLP-1 analog) • GLP-1 agonists have proved to be effective therapies to • improve glycemic control in people with T2DM; and interesting • additional effects of treatment are weight loss, • decreased appetite, and improved IR, which can prove • helpful in people with NAFLD

  17. Vitamin E • It is known that increased oxidative stress occurs in • Both NAFLD and T2DM .Consequently, besides targeting • IR or lipid synthesis mechanisms per se, another therapeutic • option for NAFLD treatment may be to decrease • oxidative stress by administration of an antioxidant such • as vitamin E. Vitamin E therapy, as compared with placebo, • was associated with significant improvements in liver enzymes • and some histological features of NASH such as • steatosis and necroinflammation

  18. Vitamin D • Preliminary experimental evidence • suggests that via effects in both adipose tissue and liver, • low serum vitaminD levels may predispose to intrahepatic • lipid accumulation and hepatic inflammation, contributing • to the development and progression of NAFLD • . However, whether vitamin D supplementation ameliorates • NAFLD is uncertain, and randomized clinical • trials are needed in man.

  19. Vitamin D

More Related